Home / Journals Journal of Drug Design and Medicinal Chemistry / Drug Discovery of New Kinases Inhibitors
Drug Discovery of New Kinases Inhibitors
Submission Deadline: Oct. 30, 2019

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
João Antunes
Department of Pharmacy, Federal University of Juiz de Fora, Governador Valadares, Minas Gerais, Brazil
Guest Editor
Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=329). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.

Special Issue Flyer (PDF)

Please download to know all details of the
Special Issue

Introduction
The development of new drugs can present several problems, such as a molecule that is a potent pharmacological inhibitor and has a possibility in the execution of its synthesis. Quinazolines are known to be capable of inhibitory kinases. Thus, a detailed study was carried out to propose new quinazolines with synthetic routes already known, and that were promising for the ability to inhibit kinases. Lipinski's five-rule in computational studies has been applied to select more promising molecules. In this study, the molecules proposed for the synthesis were systematically designed in appropriate computational programs to test several substituents of the quinazoline nucleus on the capacity of these molecules to be considered inhibitors of kinases. Six molecules were selected with the best results to inhibit kinases. In the study to evaluate the variation of substituents, the result obtained for the 8-position of the quinazoline ring and with the -Cl substituent at that ring position presented 60% of the 10 best molecules capable of inhibiting kinases. The molecular docking study confirmed that the two most promising molecules to inhibit kinase also obtained the best results to inhibit AKT kinase. Therefore, through this study it was possible to select six more promising molecules to be synthesized and available in large screening tests for several therapeutic targets known as High-Throughput Screening.

Aims and Scope:

  1. Kinase Inhibitor
  2. Quinazoline
  3. Molecular docking
  4. Chemical synthesis
  5. Cancer
  6. Drug descovery
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186